12:00 AM
Aug 20, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Reolysin: Completed Phase I enrollment

Oncolytics completed enrollment of 21 patients in the single-arm, dose-escalation U.S. Phase I REO 022 trial evaluating Reolysin in combination with FOLFIRI chemotherapy in...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >